Twisted Epithelial-to-mesenchymal Transition Promotes Progression of Surviving Bladder Cancer T24 Cells with Htert-Dysfunction.

Yan Xue,Lei Li,Dong Zhang,Kaijie Wu,Yule Chen,Jin Zeng,Xinyang Wang,Dalin He
DOI: https://doi.org/10.1371/journal.pone.0027748
IF: 3.7
2011-01-01
PLoS ONE
Abstract:BACKGROUND:Human cancer cells maintain telomeres to protect cells from senescence through telomerase activity (TA) or alternative lengthening of telomeres (ALT) in different cell types. Moreover, cellular senescence can be bypassed by Epithelial-to-mesenchymal transition (EMT) during cancer progression in diverse solid tumors. However, it has not been elucidated the characteristics of telomere maintenance and progression ability after long-term culture in bladder cancer T24 cells with hTERT dysfunction.METHODOLOGY/PRINCIPAL FINDINGS:In this study, by using a dominant negative mutant human telomerase reverse transcriptase (hTERT) vector to inhibit TA in bladder cancer T24 cells, we observed the appearance of long phenotype of telomere length and the ALT-associated PML body (APB) complex after the 27(th) passage, indicating the occurrence of ALT-like pathway in surviving T24/DN868A cells with telomerase inhibition. Meanwhile, telomerase inhibition resulted in significant EMT as shown by change in cellular morphology concomitant with variation of EMT markers. Consistently, the surviving T24/DN868A cells showed increased progression ability in vitro and in vivo. In addition, we found Twist was activated to mediate EMT in surviving T24/DN868A samples.CONCLUSIONS/SIGNIFICANCE:Taken together, our findings indicate that bladder cancer T24 cells may undergo the telomerase-to-ALT-like conversion and promote cancer progression at advanced stages through promoting EMT, thus providing novel possible insight into the mechanism of resistance to telomerase inhibitors in cancer treatment.
What problem does this paper attempt to address?